UltraPlex
UltraPlex pioneering sustainable and cost-efficient liposome-based RNA therapeutics delivery.
Status:
Pre-business
SDGs:
Good health and well-being
Industry:
Life science and medical
Impact:
Quality of life
Origin:
Research to Business
School:
School of Science
Established:
2025
The UltraPlex project develops a next-generation liposome-based drug delivery system for RNA therapeutics that is sustainable, cost-efficient, and scalable for pharmaceutical applications. Traditional liposomal formulations face challenges such as high production costs, solvent dependency, material waste, and therapeutic molecule encapsulation inefficiency issues, limiting their commercial viability. UltraPlex addresses these challenges by integrating green chemistry, nanotechnology, and focused ultrasound principles to create an eco-friendly and efficient drug delivery platform.
Contact
Christopher Fogarty
Business Developer
Read more about innovation services
News from innovation ecosystem
Finland ranks among Europe’s top investing nations, study finds
Nearly half of Finnish households now invest in stocks or mutual funds, according to a new study from Aalto University.
In summer 2026, 30 % discount on Rela massages at Rela-hierojat locations
The summer benefit is valid 1.6. – 31.8.2026.
The potential of urban greenery as a climate solution is not being fully utilized – a new handbook offers means to address this
The Handbook for carbon-smart urban green provides concrete tools for leveraging urban green spaces more effectively in climate and nature conservation efforts.